A snapshot of genetic code
Screening entire populations for breast and ovarian cancer gene mutations could prevent millions more cancer cases across the world compared to current clinical practice, according to an international study led by Queen Mary University of London. The research also shows that it is cost effective in high and upper-middle income countries.
The most well-known breast and ovarian cancer causing genes are BRCA1 and BRCA2. These gene mutations cause around 10-20 per cent of ovarian and 6 per cent of breast cancers. If mutation carriers could be identified before they develop disease, most of these cancers could be prevented by drugs, increased screening or surgery.
Current clinical guidelines globally only recommend genetic testing for high-risk women, for example, if they fulfil certain clinical criteria or if there is a strong family history of breast or ovarian cancer. However, over 50 per cent of BRCA carriers do not meet these criteria so are not tested, and over 97 per cent of BRCA carriers in the UK population remain unidentified.
This new study was supported by the NHS Innovation Accelerator Fellowship and women’s cancer charity The Eve Appeal and published in the journal Cancers. The researchers estimated the cost-effectiveness and health impact of BRCA testing in the general population, compared with current standard clinical testing of women designated as high risk, in countries considered high income (UK/USA/Netherlands), upper-middle income (China/Brazil), and low-middle income (India).
The researchers modelled a number of scenarios of population based BRCA-testing and compared the costs and health impact to the current family history based policy. Cost effectiveness was calculated from both a societal and a payer perspective. A payer perspective only includes medical costs incurred by the health system or health providers (such as costs of genetic testing, screening, prevention and cancer treatment). A societal perspective also takes into account costs such as the impact of income lost from inability to work and shorter life spans due to cancer.
The research team found that population based testing was extremely cost effective in high and upper middle income countries from a payer perspective. From a societal perspective it was cost saving in high income countries and cost effective in middle income countries like China and Brazil. Costs of BRCA testing would need to fall to around USD $172 to become cost effective in low income countries like India.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Population based BRCA-testing
- What to Know About Breast Cancer Screening Guidelines
One concern some women have is getting a false positive – a finding on a mammogram that requires a woman to return for further testing ... population. This includes: Those with the BRCA1 ...
- The Role of Estrogens in BRCA1/2 Mutation Carriers
Persons undergoing genetic testing for an inherited predisposition ... guidelines is consideration of the role of estrogens for BRCA1/BRCA2 mutation carriers. Potential implications of hormones ...
- Powell Reviews Trials of PARP Inhibition in BRCA-Positive Ovarian Cancer
During a Targeted Oncology case-based roundtable event, Matthew Powell, MD, discussed trials supporting the use of the PARP inhibitors niraparib and olaparib for patients with BRCA-positive ovarian ...
- Informing children of a mother's genetic cancer risk does not impact their health behaviors
Tercyak and Peshkin say that future studies will incorporate a more diverse population. At present, the team is focusing on evaluating a new program designed to help mothers who carry BRCA gene ...
- Liquid Biopsy: A Pathway to Earlier and Less Invasive Cancer Detection
In addition, we believe having both tissue and liquid-based ... patient population. Beyond traditional points along the cancer care continuum, we anticipate that hereditary cancer testing and ...
Go deeper with Google Headlines on:
Population based BRCA-testing
Go deeper with Bing News on:
Population based testing
- Demand Surge Seen for Patient Lifting Equipment Designed Specifically for Geriatric Population: Fact.MR Study
Currently, the global patient lifting equipment market accounts for a valuation of US$ 1.5 billion and is predicted to rise at a 7.3% CAGR through 2027.
- New methods tripled COVID-19 testing in Latinx communities
Using newly developed and culturally informed methods, a UO team was able to more than triple the number of Latinx people getting tested for COVID-19, according to a recently published research paper.
- Facebook faces suspension in Kenya over ethnic-based hate speech
The social network has reportedly failed to detect calls for ethnic-based violence ahead of Kenya's elections.
- Covid PCR tests won’t be free for general population after Cabinet decision
THE Government has decided to end free Covid tests. The decision was taken at the last meeting of Cabinet before the summer break and means people will have to pay for PCR of antigen tests – unless ...
- Concerns Around STD Testing on the Rise as Infection Rates Climb During Pandemic
In recent CDC data, racial and sexual orientation minorities, especially, have been disproportionately affected by STDs.